BJDX
Bluejay Diagnostics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.70
−6.46%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -11.4%
- EBIT
- -9.6%
- EPS
- +97.6%
- Free cash flow
- +8.9%
- Operating cash flow
- +13.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +0.3%
- EBIT
- +3.0%
- Net income
- +11.3%
- EPS
- +96.7%
- Free cash flow
- +23.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026